Biodegradable anti-reflux ureteral stent patent

The European Patent Office published application EP4713036A1 for a biodegradable, self-retentive anti-reflux ureteral stent developed by a consortium of Spanish research institutions. The patent covers a medical device designed for temporary ureteral drainage with anti-reflux properties and controlled degradation. Designated states include all current EU member states plus other EPC contracting states.

Ottobock Prosthesis Manufacturing Method Patent Application

The European Patent Office published patent application EP4574099A1 for Ottobock SE & Co. KGaA covering a method for manufacturing prosthetic devices. The application, filed by 12 named inventors, is classified under IPC codes A61F 2/50, A61F 2/76, and A61F 2/80 relating to body limbs, prosthetics, and sockets. The patent designates 34 European and associated states for protection.

Braided Stent with Improved Flexibility

The European Patent Office published patent application EP4444222A1 for Boston Scientific Scimed Inc. titled 'Braided Stent with Improved Flexibility.' The patent covers medical device technology in prosthetics (IPC A61F 2/07, A61F 2/90) with designated states across EU member states. This is a standard patent publication providing public notice of the intellectual property claim.

ViaCyte Implantable Encapsulation Device Instruments

The European Patent Office granted patent EP4289467A2 to ViaCyte, Inc. covering instruments for implantable encapsulation devices used in cell therapy applications. The patent was published March 25, 2026 and designates all EU contracting states including Germany, France, Italy, Spain, the Netherlands, Belgium, Austria, and Switzerland. ViaCyte's proprietary medical instruments for implanting and managing encapsulated therapeutic cells are now protected under European patent law.

Therapeutic HBV Vaccine Using PreS1/PreS2 Regions

The European Patent Office published patent application EP3710049A1 for a therapeutic Hepatitis B Virus (HBV) vaccine developed by the University of Washington. The patent covers the use of PreS1/PreS2 regions of the HBV envelope protein as vaccine antigens. This publication affects entities engaged in HBV vaccine research or commercialization within EPO-designated states.

Anti-MSLN Antibody Cancer Treatment Patent

European Patent Office published patent EP3699199A2 granting Green Cross Corporation and Mogam Institute for Biomedical Research exclusive rights to anti-MSLN (mesothelin) antibody compositions for cancer treatment. The patent covers antibody therapeutics targeting MSLN, a tumor-associated antigen overexpressed in several cancers including mesothelioma, pancreatic, and ovarian cancers.

Oil-Based Cosmetic Composition Patent

The European Patent Office published patent application EP3711746A1 for Pola Chemical Industries Inc., covering an oil-based cosmetic composition. The application was filed with IPC classifications including A61K 8/70, A61K 8/31, and A61Q 19/08, designating all EU member states and extension states. Inventors include DAIRAKU, Sachiko and TAKEUCHI, Satomi.

Haptoglobin for Treating Secondary Neurological Outcome Post-Hemorrhagic Stroke

The European Patent Office published patent application EP3968988A1 for haptoglobin as a therapeutic agent for treating adverse secondary neurological outcomes following hemorrhagic stroke. Co-applicants Universität Zürich and CSL Behring AG seek patent protection across 35 designated EPC contracting states including all EU member states. The A1 publication indicates the application passed formal examination and is now publicly accessible for opposition purposes.

Dietary Butyrate Therapeutic Compositions Patent

The European Patent Office published patent application EP3972428A1 for Société des Produits Nestlé S.A., covering dietary butyrate compositions and their therapeutic uses. The patent application was published March 25, 2026, with inventors HORCAJADA, PATIN, and FORBES-BLOM. Designated states cover major European markets including DE, FR, GB, IT, ES, NL, BE, CH, and others.

Ophthalmic Protein Refining Method Patent

The European Patent Office published patent EP3997123A1 for Sam Chun Dang Pharm. CO., LTD., covering a refining method for ophthalmic protein pharmaceuticals. The patent application was published March 25, 2026, with designated states covering 44 European countries. This patent grants exclusive rights to the specified protein purification method for ophthalmic applications.